{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:25:27Z","timestamp":1773458727990,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T00:00:00Z","timestamp":1377216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Evidence regarding the efficacy of gemtuzumab ozogamicin (<jats:styled-content style=\"fixed-case\">GO<\/jats:styled-content>) addition to standard induction chemotherapy in newly diagnosed acute myeloid leukaemia (<jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content>) is conflicting. This systematic review aimed to identify and summarize all evidence regarding the benefits and harms of adding <jats:styled-content style=\"fixed-case\">GO<\/jats:styled-content> to conventional chemotherapy for induction treatment of <jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content>. A comprehensive literature search of two databases (<jats:styled-content style=\"fixed-case\">PUBMED<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>ochrane) from inception up to <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>ovember 22, 2012, and 4\u00a0years of proceedings from four major haematology\/oncology conferences was undertaken. Endpoints included benefits (complete remission, relapse\u2010free, event\u2010free, and overall survival), and harms (early mortality and incidence of hepatic veno\u2010occlusive disease\/sinusoidal obstructive syndrome). Seven trials (3942 patients) met all inclusion criteria. Addition of <jats:styled-content style=\"fixed-case\">GO<\/jats:styled-content> showed improved relapse\u2010free [<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>azard <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>atio (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>)\u00a0=\u00a00\u00b784 (95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 0\u00b771\u20130\u00b799)] and event\u2010free survival [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u00a0=\u00a00\u00b759 (95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0\u00b748\u20130\u00b774)] but not overall survival [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u00a0=\u00a00\u00b795 (95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0\u00b783\u20131\u00b708)]. Addition of <jats:styled-content style=\"fixed-case\">GO<\/jats:styled-content> resulted in higher rate of early mortality [<jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>isk <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>atio\u00a0=\u00a01\u00b760 (95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 1\u00b707\u20132\u00b739)]. Improved overall survival was observed in studies using a lower cumulative <jats:styled-content style=\"fixed-case\">GO<\/jats:styled-content> dose (&lt;6\u00a0mg\/m<jats:sup>2<\/jats:sup>) [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u00a0=\u00a00\u00b789 (95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0\u00b781\u20130\u00b799)]. Addition of <jats:styled-content style=\"fixed-case\">GO<\/jats:styled-content> to conventional chemotherapy as induction therapy may improve relapse\u2010free and event\u2010free survival, but does not impact overall survival and significantly increases early mortality in <jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.12528","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T12:17:20Z","timestamp":1377260240000},"page":"315-325","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"163","author":[{"given":"Mohamed A.","family":"Kharfan\u2010Dabaja","sequence":"first","affiliation":[{"name":"Department of Blood and Marrow Transplantation H. Lee Moffitt Cancer Center Tampa FL USA"},{"name":"Department of Oncologic Sciences H. Lee Moffitt Cancer Center\/University of South Florida College of Medicine Tampa FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Myeloma &amp; Lymphoma Service Section of Hematology and Oncology West Virginia University Morgantown WV USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tea","family":"Reljic","sequence":"additional","affiliation":[{"name":"Center for Evidence\u2010Based Medicine University of South Florida College of Medicine Tampa FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Pyngolil","sequence":"additional","affiliation":[{"name":"Center for Evidence\u2010Based Medicine University of South Florida College of Medicine Tampa FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[{"name":"Department of Oncologic Sciences H. Lee Moffitt Cancer Center\/University of South Florida College of Medicine Tampa FL USA"},{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E.","family":"Lancet","sequence":"additional","affiliation":[{"name":"Department of Oncologic Sciences H. Lee Moffitt Cancer Center\/University of South Florida College of Medicine Tampa FL USA"},{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo F.","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation H. Lee Moffitt Cancer Center Tampa FL USA"},{"name":"Department of Oncologic Sciences H. Lee Moffitt Cancer Center\/University of South Florida College of Medicine Tampa FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Djulbegovic","sequence":"additional","affiliation":[{"name":"Center for Evidence\u2010Based Medicine University of South Florida College of Medicine Tampa FL USA"},{"name":"Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa FL USA"},{"name":"Department of Health Outcomes and Behavior H. Lee Moffitt Cancer Center Tampa FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Center for Evidence\u2010Based Medicine University of South Florida College of Medicine Tampa FL USA"},{"name":"Department of Health Outcomes and Behavior H. Lee Moffitt Cancer Center Tampa FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,23]]},"reference":[{"issue":"1","key":"e_1_2_7_2_1","first-page":"446","article-title":"The sequential combination of gemtuzumab ozogamicin and intensive chemotherapy does not benefit older patients with untreated AML: results of the EORTC\u2010GIMEMA AML\u201017 randomized trial","volume":"97","author":"Amadori S.","year":"2012","journal-title":"Haematologica"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr346"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.4310"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2964"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0772"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470693926.ch16"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gentuzumab ozogamycin to chemotherapy improves event\u2010free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML2006 IR study","volume":"118","author":"Delaunay J.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_10_1","article-title":"Pfizer to withdraw a cancer drug Mylotarg","author":"Dooren J.","year":"2010","journal-title":"Wall Street Journal"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60534-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4354"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904544"},{"key":"e_1_2_7_14_1","first-page":"182","article-title":"Remission rates in childhood acute myeloid leukemia (AML) utilizing a dose\u2010intensive induction regimen with or without Gemtuzumab Ozogamicin (GO): initial results from the Children's Oncology Group Phase III Trial, AAML0531","volume":"116","author":"Gamis A.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38446.498542.8F"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_7_17_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins J.P.","year":"2011"},{"key":"e_1_2_7_18_1","volume-title":"FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg From U.S. Market","author":"Jefferson E.","year":"2010"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901409"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.6592"},{"key":"e_1_2_7_22_1","first-page":"790","article-title":"Preliminary Results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of Gemtuzumab Ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post\u2010consolidation Gemtuzumab Ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia","volume":"114","author":"Petersdorf S.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_23_1","unstructured":"Petersdorf S. Slovak M. Willman C. Kopecky K. Gundacker H. Maher T.&White C.(2010)A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg\u00ae) Induction Therapy versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post\u2010Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg\u00ae) or No Additional Therapy for Patients under Age 61 with Previously Untreated de novo Acute Myeloid Leukemia (AML).http:\/\/www.mhlw.go.jp\/stf\/shingi\/2r9852000000vrz2-att\/2r9852000000vs34.pdf"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2310"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.83"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.0132"},{"key":"e_1_2_7_28_1","unstructured":"RevMan(2011)Review Manager. The Cochrane Collaboration\u2010available on the world wide web athttp:\/\/www.cochrane.org\/cochrane\/revman.htm Copenhagen."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490482"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0255"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1066"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12528","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:06:48Z","timestamp":1696363608000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,23]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1111\/bjh.12528"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12528","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,23]]},"assertion":[{"value":"2013-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-07-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}